2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
D

Updates on Advanced GE Cancers: 2L FOLFIRI + Ramucirumab vs. Paclitaxel + Ramucirumab, T-DXd in HER2+Disease

By 2020 ASCO Virtual Direct™ Highlights FEATURING Daniel Catenacci
By 2020 ASCO Virtual Direct™ Highlights FEATURING Daniel Catenacci
383 views
September 16, 2020
1 Comment
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
GI
07:15
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on Rectal & Esophageal Cancer: What Are the OP…

Feat. K. Mirabeau-Beale
36:52
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on CRC: Pembro vs. Chemo for MSI-H/dMMR Metasta…

Feat. C. Gomez
08:49
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on mCRC: FDA Approved Encorafenib + Cetuximab Comb…

Feat. C. Gomez
07:19
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on HER2-Expressing mCRC: Was There Any Activity in…

Feat. C. Gomez
07:11
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage 3 Rectal Cancer: Can We Reduce Distant…

Feat. C. Gomez
19:57
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on GE Adenocarcinomas: How Does Neoadjuvant Trastu…

Feat. D. Catenacci
09:58
2020 ASCO Virtual Direct™ Highlights

Updates on Advanced GE Cancers: 2L FOLFIRI + Ramucirumab vs. Paclita…

Feat. D. Catenacci
05:59
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Pancreatic Cancer: Perioperative Chemo + mFO…

Feat. D. Catenacci